journal
MENU ▼
Read by QxMD icon Read
search

Urologic Oncology

journal
https://www.readbyqxmd.com/read/28302349/influence-of-pathologist-experience-on-positive-surgical-margins-following-radical-prostatectomy
#1
Jacob E Tallman, Vignesh T Packiam, Kristen E Wroblewski, Gladell P Paner, Scott E Eggener
BACKGROUND: A positive surgical margin (PSM) following radical prostatectomy (RP) for prostate cancer is associated with increased risk of biochemical recurrence. We sought to examine whether the pathologist is an independent predictor of PSMs. METHODS: We performed a retrospective review of 3,557 men who underwent RP for localized prostate cancer at our institution from 2003 to 2015. We evaluated 29 separate pathologists. Univariate and multivariable logistic regression were used to test variables previously shown to influence PSM rates...
March 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28291637/is-the-cancer-genome-atlas-tcga-bladder-cancer-cohort-representative-of-invasive-bladder-cancer
#2
Roland Seiler, Peter C Black, George Thalmann, Arnulf Stenzl, Tilman Todenhöfer
PURPOSE: The Cancer Genome Atlas (TCGA) Research Consortium has conducted a comprehensive molecular characterization of invasive bladder cancer (BCa). This open-access dataset has become the critical reference for studying biomarkers and mechanisms of disease in BCa. In order for this data to be considered representative, and to allow comparisons of markers between cohorts, clinicopathologic characteristics of this cohort need to conform to those established for this disease state. The aim of this study was to critically evaluate clinicopathologic characteristics and outcomes of the TCGA BCa cohort in comparison with published cystectomy series...
March 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28291636/correlation-between-messenger-rna-expression-and-protein-expression-of-immune-checkpoint-associated-molecules-in-bladder-urothelial-carcinoma-a-retrospective-study
#3
Constance Le Goux, Diane Damotte, Sophie Vacher, Mathilde Sibony, Nicolas Barry Delongchamps, Anne Schnitzler, Benoit Terris, Marc Zerbib, Ivan Bieche, Géraldine Pignot
OBJECTIVES: Immunotherapy for bladder cancer seems to have promising results. Here, we evaluated the association between messenger RNA (mRNA) and protein levels and possible prognostic value of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immune checkpoint pathways during bladder carcinogenesis. METHODS AND MATERIALS: Tumor samples were obtained from 155 patients (84 with muscle-invasive bladder cancer [MIBC], and 71 non-muscle-invasive bladder cancer [NMIBC]) and normal bladder tissue from 15 patients...
March 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28284894/can-partial-nephrectomy-provide-equal-oncological-efficiency-and-safety-compared-with-radical-nephrectomy-in-patients-with-renal-cell-carcinoma-%C3%A2-4cm-a-propensity-score-matched-study
#4
Hakmin Lee, Jong Jin Oh, Seok Soo Byun, Chang Wook Jeong, Cheol Kwak, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Seong Il Seo
OBJECTIVE: Although partial nephrectomy (PN) is the standard treatment for localized clinical T1a renal cell carcinoma (RCC), treatment of larger renal tumors is controversial. We evaluated the oncological outcomes and perioperative complications after radical and PN for RCC ≥4cm. PATIENTS AND METHODS: We retrospectively analyzed the data of 2,373 patients surgically treated for nonmetastatic RCC with clinical T1b or T2 (≥4cm). The propensity scores for surgery type were calculated, and the partial group was matched to the radical group in a 1:3 ratio...
March 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28284893/gstm1-genotype-is-an-independent-prognostic-factor-in-clear-cell-renal-cell-carcinoma
#5
Vesna M Coric, Tatjana P Simic, Tatjana D Pekmezovic, Gordana M Basta-Jovanovic, Ana R Savic-Radojevic, Sanja M Radojevic-Skodric, Marija G Matic, Sonja R Suvakov, Dejan P Dragicevic, Tanja M Radic, Zoran M Dzamic, Marija S Pljesa-Ercegovac
PURPOSE: Owing to dual functionality of cytosolic glutathione S-transferases (GSTs), they might affect both the development and the progression of renal cell carcinoma (RCC). However, the data on the prognostic value of GST polymorphism in patients with RCC are scarce. Hence, we evaluated the effect of GST gene variants on both the risk of RCC development and the postoperative prognosis in patients with clear cell RCC (ccRCC). METHODS: GST genotypes were determined in 305 patients with RCC and 326 matched controls, whereas the overall survival was evaluated in patients with ccRCC only...
March 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28284892/body-mass-index-and-the-clinicopathological-characteristics-of-clinically-localized-renal-masses-an-international-retrospective-review
#6
Efrat Tsivian, Matvey Tsivian, Kae Jack Tay, Thomas Longo, Ziv Zukerman, Giuseppe Martorana, Riccardo Schiavina, Eugenio Brunocilla, Thomas J Polascik
OBJECTIVES: To investigate the potential association between body mass index (BMI) and clinicopathological features of clinically localized renal masses. MATERIALS AND METHODS: An international, multi-institutional retrospective review of patients who underwent surgery for clinically localized renal masses between 2000 and 2010 was undertaken after an institutional review board approval. Patients were divided into 4 absolute BMI groups based on the entire cohort׳s percentiles and 4 relative BMI groups based on their respective population (American or Italian)...
March 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28284891/loss-of-bap1-protein-expression-in-the-first-metastatic-site-predicts-prognosis-in-patients-with-clear-cell-renal-cell-carcinoma
#7
Yuji Miura, Naoko Inoshita, Masaomi Ikeda, Yu Miyama, Ryosuke Oki, Suguru Oka, Chihiro Kondoh, Yukinori Ozaki, Yuko Tanabe, Kazuhiro Kurosawa, Shinji Urakami, Tadasu Kohno, Toshikazu Okaneya, Toshimi Takano
OBJECTIVES: To investigate the intratumoral heterogeneity of BAP1 and PBRM1 expression at the primary site and metastatic sites and to evaluate whether BAP1 and PBRM1 expression in metastatic sites of clear cell renal cell carcinoma (ccRCC) has prognostic value. METHODS AND MATERIALS: We collected paired samples from the primary site and the first metastatic site in 41 patients with ccRCC. Immunohistochemistry analyses were performed for the expression of BAP1 and PBRM1 proteins...
March 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28284890/access-to-high-volume-surgeons-and-the-opportunity-cost-of-performing-radical-prostatectomy-by-low-volume-providers
#8
Afsaneh Barzi, Eric A Klein, Siamak Daneshmand, Inderbir Gill, David I Quinn, Sarmad Sadeghi
BACKGROUND: Evidence suggests that redirecting surgeries to high-volume providers may be associated with better outcomes and significant societal savings. Whether such referrals are feasible remains unanswered. METHODS: Medicare Provider Utilization and Payment Data, SEER 18, and US Incidence data were used to determine the geographic distribution and radical prostatectomy volume for providers. Access was defined as availability of a high-volume provider within driving distance of 100 miles...
March 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28283376/navigating-the-evolving-therapeutic-landscape-in-advanced-prostate-cancer
#9
REVIEW
E David Crawford, Daniel Petrylak, Oliver Sartor
Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year. The overall 5-year survival rate for prostate cancer is very high. Up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop castration-resistant prostate cancer (CRPC) within 5 years, with median survival for those with metastatic CRPC ranging from approximately 15 to 36 months in recent studies. With the advent of several new drugs in the past 5 years to treat CRPC, the challenge facing clinicians is how to best sequence or combine therapies or both to optimize outcomes...
March 7, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28259541/nivolumab-treatment-for-advanced-renal-cell-carcinoma-considerations-for-clinical-practice
#10
REVIEW
Richard W Joseph, Gurkamal Chatta, Ulka Vaishampayan
BACKGROUND: Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. METHODS AND PURPOSE: This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management...
March 2, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28256311/racial-differences-in-prostate-specific-antigen-based-prostate-cancer-screening-state-by-state-and-region-by-region-analyses
#11
Tarun Jindal, Naveen Kachroo, Jesse Sammon, Deepansh Dalela, Akshay Sood, Malte W Vetterlein, Patrick Karabon, Wooju Jeong, Mani Menon, Quoc-Dien Trinh, Firas Abdollah
OBJECTIVE: Black men are more prone to harbor prostate cancer. They are more likely to succumb to this tumor than their White counterparts and may benefit from early detection and treatment. In this study, we assess the nationwide and regional disparity in prostate-specific antigen (PSA) screening for prostate cancer between Black men and non-Hispanic Whites (NHWs). METHODS: A total of 247,079 (weighted 55,185,102) men, aged 40 to 99 years, who responded to the 2012 and 2014 behavioral risk factor surveillance system surveys were used for our analysis...
February 27, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28233671/the-prognostic-value-of-the-neutrophil-lymphocyte-ratio-in-renal-oncology-a-review
#12
REVIEW
Romain Boissier, Jennifer Campagna, Nicolas Branger, Gilles Karsenty, Eric Lechevallier
BACKGROUND: The neutrophil-lymphocyte ratio (NLR) is a biological marker of inflammation with a significant prognostic value in the field of oncology. AIM: In this review, we discuss the prognostic value of the NLR in renal cell carcinoma (RCC). MATERIAL AND METHOD: We conducted a literature review of the PubMed database in August 2016. Initial research identified 31 publications. Following full-text screening, 15 studies were finally included: 7 studies concerning metastatic or locally advanced renal cancer, 6 studies dealing with localized renal cancer, 2 articles evaluating the NLR in renal cancer whatever the status of the disease (metastatic or localized)...
February 20, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28215740/inhibition-of-htert-expression-by-map-kinase-inhibitor-induces-cell-death-in-renal-cell-carcinoma
#13
Deeksha Pal, Ujjawal Sharma, Shrawan Kumar Singh, Nandita Kakkar, Rajendra Prasad
BACKGROUND: Human telomerase reverse transcriptase (hTERT) is one of the components of telomerase enzyme and its activity is associated with cell proliferation and differentiation. Extracellular signal regulated kinase (ERK)-mitogen activated protein kinase signaling pathway play an important role in hTERT expression. The present study was conducted to ascertain hTERT messenger RNA (mRNA) expression in renal cell carcinoma (RCC) and its association with clinicopathological characteristics...
February 16, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214284/basic-translational-science-survey-section-kidney-cancer
#14
Jodi K Maranchie
No abstract text is available yet for this article.
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214283/prognostic-role-of-n-cadherin-expression-in-patients-with-non-muscle-invasive-bladder-cancer
#15
Mohammad Abufaraj, Shahrokh F Shariat, Andrea Haitel, Marco Moschini, Beat Foerster, Piotr Chłosta, Kilian Gust, Marek Babjuk, Alberto Briganti, Pierre I Karakiewicz, Walter Albrecht
PURPOSE: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy. PATIENTS AND METHODS: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214282/basic-translational-science-survey-section-kidney-cancer
#16
Jodi K Maranchie
No abstract text is available yet for this article.
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214281/patient-characterization-and-usage-trends-of-proton-beam-therapy-for-localized-prostate-cancer-in-the-united-states-a-study-of-the-national-cancer-database
#17
Arya Amini, David Raben, E David Crawford, Thomas W Flaig, Elizabeth R Kessler, Elaine T Lam, Paul Maroni, Thomas J Pugh
PURPOSE: To evaluate usage trends and identify factors associated with proton beam therapy (PBT) compared to alternative forms of external beam radiation therapy (RT) (EBRT) for localized prostate cancer. PATIENTS AND METHODS: The National Cancer Database was queried for men with localized (N0, M0) prostate cancer diagnosed between 2004 and 2013, treated with EBRT, with available data on EBRT modality (photon vs. PBT). Binary multiple logistic regression identified variables associated with EBRT modality...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214280/current-guidelines-do-not-sufficiently-discriminate-venous-thromboembolism-risk-in-urology
#18
Kristen McAlpine, Rodney H Breau, Ranjeeta Mallick, Sonya Cnossen, Ilias Cagiannos, Christopher Morash, Marc Carrier, Luke T Lavallée
PURPOSE: Venous thromboembolism (VTE) is the leading cause of noncancer death following major cancer surgery. Current thromboprophylaxis guidelines do not address procedure-specific risk of venous thromboembolism for urological patients. This project was created to determine the risk and timing of VTE after major urological surgery and to evaluate if surgical procedure was an independent risk factor for VTE after adjusting for previously established risk factors. MATERIAL AND METHODS: The American College of Surgeons׳ National Surgical Quality Improvement Program was used to create a cohort of patients who received major abdominal or pelvic urologic surgery between 2006 and 2014...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214279/basic-translational-science-survey-section-kidney-cancer
#19
Jodi K Maranchie
No abstract text is available yet for this article.
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28202224/the-metastatic-potential-of-renal-tumors-influence-of-histologic-subtypes-on-definition-of-small-renal-masses-risk-stratification-and-future-active-surveillance-protocols
#20
Michael Daugherty, Dillon Sedaghatpour, Oleg Shapiro, Srinivas Vourganti, Alexander Kutikov, Gennady Bratslavsky
OBJECTIVE: The influence of histology in metastatic potential is often overlooked when discussing the management options of small renal masses (SRM), with size or growth rate often serving as the triggers for the intervention. We aim to re-examine the definition of a SRM by evaluating the metastatic potential of renal masses incorporating tumor size and histology to create metastatic risk tables. MATERIALS AND METHODS: Surveillance Epidemiology and End Results (SEER)-18 registries database was queried for all cases of clear cell, papillary, and chromophobe renal cell carcinoma (RCC) diagnosed between 2004 and 2012...
February 12, 2017: Urologic Oncology
journal
journal
32958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"